BTK inhibitor demonstrated non-inferior progression-free survival compared to Imbruvica
News
NHS COVID-19 vaccination drive bolstered by new centres
Over 30 new vaccination centres open across England
Psychiatry Consortium funds project investigating new schizophrenia treatments
Project will see the University of Oxford partner with the Earlham Institute, Biogen and Boehringer Ingelheim
EU approval for Bavencio in bladder cancer
Approved for the maintenance treatment of advanced urothelial carcinoma
Servier and MiNA Therapeutics ink neurology pact
Companies will develop saRNA therapies to treat neurological diseases
US green light for long-acting HIV regimen Cabenuva
Cabenuva consists of ViiV Healthcare’s cabotegravir and Janssen’s rilpivirine
Gilead’s Veklury should be effective against COVID-19 variants
Company has completed genetic analysis for UK and South African variants
NICE no for BMS’ multiple sclerosis drug Zeposia
Cost-effectiveness estimates ‘uncertain’, according to NICE
US approval for MSD’s heart failure med Verquvo
Drug approved to reduce the risk of cardiovascular death/heart failure hospitalisation
RCP survey finds over 1 in 4 doctors sought mental health support during pandemic
Large number of respondents reported feeling tired or exhausted
NICE publishes final guidance backing Jyseleca for rheumatoid arthritis
Over 400,000 people in the UK live with RA
Pfizer, BioNTech’s COVID-19 vaccine likely to be effective against UK strain
Antibodies in blood of vaccinated individuals neutralised in vivo version of variant
Sanofi’s RSV treatment nirsevimab awarded PIM status
PIM status was awarded on the basis of Phase IIb results of nirsevimab
Amryt’s Myalepta scores NICE backing for rare lipid disorder
Lipodystrophy is characterised by an abnormal distribution of fat in the body
ConserV Bioscience to develop ‘broad-spectrum’ coronavirus vaccine
UK biotech company will collaborate with Lawrence Livermore National Laboratory
